2023
Age-related, multivariate associations between white matter microstructure and behavioral performance in three executive function domains
Anderson J, Calhoun V, Pearlson G, Hawkins K, Stevens M. Age-related, multivariate associations between white matter microstructure and behavioral performance in three executive function domains. Developmental Cognitive Neuroscience 2023, 64: 101318. PMID: 37875033, PMCID: PMC10618425, DOI: 10.1016/j.dcn.2023.101318.Peer-Reviewed Original ResearchConceptsExecutive function domainsResponse inhibitionWhite matter microstructureLower response inhibitionStructure-cognition relationshipsEF abilitiesBehavioral performanceCognitive imbalanceNeurocognitive testsFunction domainTest performanceYoung adulthoodFractional anisotropyBrain changesAge 12Young adultsSS performanceWhite matter FA valuesGreater relianceWhite matter changesWhite matter microstructural differencesSubjects ages 12White matter skeletonIndependent componentsMultivariate associations
2018
Relationship between fMRI response during a nonverbal memory task and marijuana use in college students
Dager AD, Tice MR, Book GA, Tennen H, Raskin SA, Austad CS, Wood RM, Fallahi CR, Hawkins KA, Pearlson GD. Relationship between fMRI response during a nonverbal memory task and marijuana use in college students. Drug And Alcohol Dependence 2018, 188: 71-78. PMID: 29754029, PMCID: PMC6756147, DOI: 10.1016/j.drugalcdep.2018.03.025.Peer-Reviewed Original ResearchConceptsInferior frontal gyrusMJ usersFMRI responsesCollege studentsMemory taskMJ useFunctional magnetic resonance imaging (fMRI) responsesNonverbal memory tasksLower fMRI responseRecognition memoryNeural correlatesMagnetic resonance imaging responseFrontal gyrusVisual encodingRecognition taskOccupational functioningAge 18Memory dysfunctionMarijuana useAcademic performanceLeft hippocampusHippocampal dysfunctionGroup differencesRight hippocampusTaskLongitudinal Effects of Alcohol Consumption on the Hippocampus and Parahippocampus in College Students
Meda SA, Hawkins KA, Dager AD, Tennen H, Khadka S, Austad CS, Wood RM, Raskin S, Fallahi CR, Pearlson GD. Longitudinal Effects of Alcohol Consumption on the Hippocampus and Parahippocampus in College Students. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2018, 3: 610-617. PMID: 29680476, PMCID: PMC6062479, DOI: 10.1016/j.bpsc.2018.02.006.Peer-Reviewed Original ResearchConceptsAlcohol consumptionAlcohol use indicesHippocampal volume declineBrain magnetic resonanceLongitudinal effectsMemory scoresCalifornia Verbal Learning Test-IIAlcohol-induced memory blackoutsPara-hippocampusHippocampal volumeMemory blackoutsLongitudinal brainVolume declineDrinking indicesLongitudinal pipelinePoorer memory performancePoorer memory scoresHippocampusTest IICross-sectional literatureDrinking-related measuresBrainAlcohol researchMagnetic resonanceScores
2017
Longitudinal influence of alcohol and marijuana use on academic performance in college students
Meda SA, Gueorguieva RV, Pittman B, Rosen RR, Aslanzadeh F, Tennen H, Leen S, Hawkins K, Raskin S, Wood RM, Austad CS, Dager A, Fallahi C, Pearlson GD. Longitudinal influence of alcohol and marijuana use on academic performance in college students. PLOS ONE 2017, 12: e0172213. PMID: 28273162, PMCID: PMC5342177, DOI: 10.1371/journal.pone.0172213.Peer-Reviewed Original ResearchComposite impulsivity-related domains in college students
Khadka S, Stevens MC, Aslanzadeh F, Narayanan B, Hawkins KA, Austad CS, Raskin SA, Tennen H, Wood RM, Fallahi C, Potenza MN, Pearlson GD. Composite impulsivity-related domains in college students. Journal Of Psychiatric Research 2017, 90: 118-125. PMID: 28273441, DOI: 10.1016/j.jpsychires.2017.02.016.Peer-Reviewed Original ResearchConceptsConfirmatory factor analysisAttention deficit hyperactivity disorderCollege studentsImpulsivity-related constructsImpulsivity/compulsivityComputerized behavioral measuresDeficit hyperactivity disorderImpulsivity-related behaviorsSelf-report assessmentsSubsequent psychometric analysesHyperactivity disorderBehavioral measuresDistinct constructsImpulsive actionAppetite motivationMultidimensional constructMultiple regression analysisDisorder riskNaturalistic frameworkSimilar analytical approachPsychometric analysisFactor analysisFuture researchIndependent samplesCurrent study
2014
Genetic association of impulsivity in young adults: a multivariate study
Khadka S, Narayanan B, Meda SA, Gelernter J, Han S, Sawyer B, Aslanzadeh F, Stevens MC, Hawkins KA, Anticevic A, Potenza MN, Pearlson GD. Genetic association of impulsivity in young adults: a multivariate study. Translational Psychiatry 2014, 4: e451-e451. PMID: 25268255, PMCID: PMC4199418, DOI: 10.1038/tp.2014.95.Peer-Reviewed Original Research
2013
Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial
Hoffman RE, Wu K, Pittman B, Cahill JD, Hawkins KA, Fernandez T, Hannestad J. Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial. Biological Psychiatry 2013, 73: 1008-1014. PMID: 23485015, PMCID: PMC3641174, DOI: 10.1016/j.biopsych.2013.01.016.Peer-Reviewed Original Research
2012
The course of cognitive functioning over six months in individuals at clinical high risk for psychosis
Barbato M, Colijn MA, Keefe RS, Perkins DO, Woods SW, Hawkins KA, Christensen BK, Addington J. The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. Psychiatry Research 2012, 206: 195-199. PMID: 23159196, PMCID: PMC3600156, DOI: 10.1016/j.psychres.2012.10.013.Peer-Reviewed Original ResearchConceptsClinical high riskCHR individualsComprehensive cognitive test batteryCognitive test batteryCognitive impairmentFuture longitudinal researchCognitive functioningCognitive performanceCognitive testsTest batteryLongitudinal researchCognitionPoor performanceLongitudinal changesPsychosisIndividualsParticipantsImpairmentBaseline participantsFunctioningPerformanceBatteriesResearchProdromeGlycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms
2010
Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis
Seidman LJ, Giuliano AJ, Meyer EC, Addington J, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Tsuang MT, Walker EF, Woods SW, Bearden CE, Christensen BK, Hawkins K, Heaton R, Keefe RS, Heinssen R, Cornblatt BA. Neuropsychology of the Prodrome to Psychosis in the NAPLS Consortium: Relationship to Family History and Conversion to Psychosis. JAMA Psychiatry 2010, 67: 578-588. PMID: 20530007, PMCID: PMC3332118, DOI: 10.1001/archgenpsychiatry.2010.66.Peer-Reviewed Original ResearchConceptsFamily historyCHR individualsNeuropsychological functioningCHR syndromeNorth American Prodrome Longitudinal StudyClinical high-risk individualsHigh-risk groupFirst-episode schizophreniaBaseline neuropsychological evaluationHigh-risk individualsSecond-degree relativesHigh-risk statusLongitudinal studyGlobal neuropsychological functioningWorse verbal memoryPrediction of psychosisCHR assessmentSyndrome criteriaProspective evaluationClinical criteriaModerate severityNeurocognitive composite scorePsychosis onsetNormal controlsSubsequent psychosisIncidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, Hawkins KA, Gueorguieva RV, Glazer WM. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. The Journal Of Clinical Psychiatry 2010, 71: 463-74. PMID: 20156410, PMCID: PMC3109728, DOI: 10.4088/jcp.07m03890yel.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAmbulatory CareAntipsychotic AgentsCohort StudiesCommunity Mental Health CentersConnecticutDiagnostic and Statistical Manual of Mental DisordersDyskinesia, Drug-InducedFemaleHumansIncidenceLongitudinal StudiesMaleMental DisordersMiddle AgedPrevalenceProspective StudiesPsychiatric Status Rating ScalesRisk FactorsSeverity of Illness IndexConceptsProspective cohort studyConventional antipsychoticsTardive dyskinesiaAtypical antipsychoticsCohort studyPrevious prospective cohort studyCommunity mental health centerConventional antipsychotic medicationsMental health centersAntipsychotic medicationHealth centersBaseline evaluationAntipsychoticsNew diagnosisDyskinesiaClinical practicePsychiatric outpatientsRecent exposureIncidencePrevious visitPrevious studiesPrevalenceSubjectsCurrent studyMost previous studies
2008
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research 2008, 105: 1-9. PMID: 18774696, DOI: 10.1016/j.schres.2008.07.008.Peer-Reviewed Original ResearchConceptsNeuropsychological courseDouble-blind treatment studyNeuropsychological StatusPlacebo-assigned subjectsPutative prodromal stateDouble-blind trialFrank psychotic episodeEarly convertersOlanzapine treatmentNeuropsychological deficienciesFrank psychosisMedication studiesFirst episodePsychotic episodeProdromal stateHigh riskBlind trialNeuropsychological declineTreatment studiesPsychotic conditionsPsychosisLate convertersOlanzapineProdromeInitial assessment
2007
Aripiprazole in the treatment of the psychosis prodrome
Woods SW, Tully EM, Walsh BC, Hawkins KA, Callahan JL, Cohen SJ, Mathalon DH, Miller TJ, McGlashan TH. Aripiprazole in the treatment of the psychosis prodrome. The British Journal Of Psychiatry. Supplement 2007, 191: s96-s101. PMID: 18055946, DOI: 10.1192/bjp.191.51.s96.Peer-Reviewed Original ResearchConceptsPsychosis prodromeMixed-effects repeated-measures analysisShort-term efficacySymptom total scoreSingle-site trialRepeated-measures analysisAripiprazole treatmentAdverse eventsFinal visitSafety profilePromising efficacyProdromal phasePsychotic disordersScale scoreBaseline levelsWeight gainFirst weekProdromeTotal scoreAripiprazoleTreatmentNeuropsychological measuresPreliminary evidenceWeeksEfficacy
2006
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal Of Psychiatry 2006, 163: 790-799. PMID: 16648318, DOI: 10.1176/ajp.2006.163.5.790.Peer-Reviewed Original ResearchConceptsOlanzapine patientsPlacebo patientsProdromal symptomsPsychosis ratesDouble-blind treatment periodEfficacy of olanzapineFurther treatment researchOlanzapine Versus PlaceboOlanzapine-treated patientsDouble-blind trialPhase of illnessPositive prodromal symptomsInduced Weight GainHazard of conversionSignificant differencesNorth American clinicsSignificant treatment differencesOlanzapine groupVersus PlaceboPlacebo groupSymptom scoresEfficacy measuresWeek 8Treatment periodPatients
2004
Factorial structure of the Scale of Prodromal Symptoms
Hawkins KA, McGlashan TH, Quinlan D, Miller TJ, Perkins DO, Zipursky RB, Addington J, Woods SW. Factorial structure of the Scale of Prodromal Symptoms. Schizophrenia Research 2004, 68: 339-347. PMID: 15099615, DOI: 10.1016/s0920-9964(03)00053-7.Peer-Reviewed Original ResearchNeuropsychological status of subjects at high risk for a first episode of psychosis
Hawkins KA, Addington J, Keefe RS, Christensen B, Perkins DO, Zipurksy R, Woods SW, Miller TJ, Marquez E, Breier A, McGlashan TH. Neuropsychological status of subjects at high risk for a first episode of psychosis. Schizophrenia Research 2004, 67: 115-122. PMID: 14984870, DOI: 10.1016/j.schres.2003.08.007.Peer-Reviewed Original ResearchConceptsFirst episodeFirst psychotic episodeLevel of impairmentSchizophrenia prodromePsychotic episodeHigh riskMulti-site studyProdromal interventionPopulation normsNeuropsychological examNeuropsychological StatusNeuropsychological functioningNormal intelligenceEpisodesSchizophrenia samplePsychosisSubjectsRiskStatusProdromeSchizophreniaImpairmentSeverity
2003
Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome
Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, Hawkins KA, Marquez E, Lindborg SR, Tohen M, McGlashan TH. Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003, 54: 453-464. PMID: 12915290, DOI: 10.1016/s0006-3223(03)00321-4.Peer-Reviewed Original ResearchConceptsExtrapyramidal symptomsPlacebo-controlled trialShort-term efficacyTrial of olanzapineTreatment x time interactionGreater symptomatic improvementSymptom total scoreX time interactionGreater weight gainRepeated-measures analysisOlanzapine patientsSchizophrenic prodromeOlanzapine treatmentPlacebo patientsSymptomatic improvementAcute treatmentMore patientsOlanzapine 5Prodromal symptomsRoutine treatmentProdromal patientsProdromal phaseWeek 8Week 6PlaceboThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample. Schizophrenia Research 2003, 61: 19-30. PMID: 12648732, DOI: 10.1016/s0920-9964(02)00440-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBenzodiazepinesBipolar DisorderComorbidityDepressive Disorder, MajorDouble-Blind MethodFemaleHumansMaleMood DisordersOlanzapinePirenzepinePsychomotor DisordersPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySleep Wake DisordersSpeech DisordersConceptsFirst-episode schizophreniaEpisode schizophreniaTreatment-seeking patientsClinical trialsDouble-blind placebo-controlled clinical trialProdromal SyndromesDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsMild affective symptomsNew diagnostic criteriaSerious mental illnessClinical trial samplesUntreated first-episode schizophreniaSubstance use/abuseEffects of drugsPutative prodromal syndromeUse/abuseUnusual thought contentAdolescent maniaOngoing symptomatologyProdromal sampleStudy medicationBaseline characteristicsMost patientsThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design. Schizophrenia Research 2003, 61: 7-18. PMID: 12648731, DOI: 10.1016/s0920-9964(02)00439-5.Peer-Reviewed Original ResearchConceptsPsychosis onsetClinical trialsDouble-blind placebo-controlled clinical trialStudy rationaleDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsNew diagnostic criteriaClinical trial designPutative prodromal syndromeTreatment-seeking patientsOngoing symptomatologyNeuroleptic medicationHigh riskDiagnostic criteriaTrial designEarly courseProdromal SyndromesClinical phenomenologyStudy designClinical populationsPatientsOnsetIntervention researchTrials
2001
The influence of IQ stratification on WAIS-III/WMS-III FSIQ-general memory index discrepancy base-rates in the standardization sample.
Hawkins KA, Tulsky DS. The influence of IQ stratification on WAIS-III/WMS-III FSIQ-general memory index discrepancy base-rates in the standardization sample. Journal Of The International Neuropsychological Society 2001, 7: 875-80. PMID: 11771631, DOI: 10.1017/s1355617701777119.Peer-Reviewed Original Research